Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used a murine model of MM with transgenic overexpression of the unfolded protein response sensor X-box binding protein 1 (XBP1s) in the B cell compartment to define MM stem cells.
|
30944260 |
2019 |
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MM cells may co-opt the IRE1α-XBP1s pathway; however, the validity of IRE1α as a potential MM therapeutic target is controversial.
|
31371506 |
2019 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The identified immunogenic HLA-A24-specific XBP1 unspliced (UN)<sub>185-193</sub> (I S P W I L A V L), XBP1 spliced (SP)<sub>223-231</sub> (V Y P E G P S S L), CD138<sub>265-273</sub> (I F A V C L V G F) and CS1<sub>240-248</sub> (L F V L G L F L W) peptides induced antigen-specific CTL with anti-MM activity in an HLA-A24 restricted manner.
|
29089645 |
2018 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The endoplasmic reticulum kinase inositol-requiring enzyme 1 (IRE1) and its downstream target X-box-binding protein 1 (XBP1) drive B-cell differentiation toward plasma cells and have been shown to contribute to multiple myeloma development; yet, little is known of the role of this pathway in diffuse large B-cell lymphoma (DLBCL).
|
28167662 |
2017 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression level of Xbp-1s was measured in 4 MM cell lines and correlated with sensitivity to bortezomib.
|
27647225 |
2017 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study not only confirmed the utilization of topological data analysis in drug discovery but also identified a class of compounds with a unique mechanism of action as potent IRE1α-XBP1 inhibitors in the treatment of multiple myeloma.
|
27307600 |
2016 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, siRNA knockdown of XBP-1 disrupted TM- or DTT-induced myeloma cell differentiation and maturation.
|
24356728 |
2015 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, SCH727965 diminished myeloma cell growth in vivo in association with XBP-1s downregulation.
|
24362465 |
2014 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that targeting XBP-1 has potential as a treatment strategy, not only for multiple myeloma, but also for mature B cell leukemia and lymphoma.
|
24812669 |
2014 |
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic deletion of gp96 in XBP1s-Tg mice attenuates multiple myeloma.
|
24077352 |
2013 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results demonstrate that blockade of XBP1 splicing by inhibition of IRE1α endoribonuclease domain is a potential therapeutic option in MM.
|
22538852 |
2012 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results demonstrate that XBP1s is a pathogenic factor underlying BMSC support of MM cell growth and osteoclast formation and therefore represents a therapeutic target for MM bone disease.
|
22427205 |
2012 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of XBP-1 and other regulators of the unfolded protein response were measured in myeloma and other cancer cell lines and two cohorts of patients with refractory myeloma and correlated with sensitivity/response to bortezomib.
|
21993678 |
2012 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have determined the gene expression levels of IRE1alpha, XBP1, XBP1UNSPLICED (XBP1u), and XBP1SPLICED (XBP1s) in a series of patients with myeloma and correlated findings with clinical outcome.
|
20421453 |
2010 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
None of the low-grade lymphomas showed evidence of Xbp-1 activation; however, Xbp-1 activation was found in 28% of diffuse large B-cell lymphomas, independent of germinal or postgerminal center phenotype, as well as in 48% of plasmablastic lymphomas and 69% of plasma-cell neoplasms.
|
19389935 |
2009 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blimp-1 ASODN and Xbp-1 ASODN clearly inhibited myeloma cell differentiation and significantly partially inhibited the differentiation effects induced by 2ME2 at low concentration, whereas PAX-5 ASODN clearly induced myeloma cell differentiation and significantly enhanced 2ME2-induced differentiation effects.
|
18192112 |
2007 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The similarities of this model with the human disease, coupled with documented frequent XBP-1s overexpression in human MM, serve to implicate XBP-1s dysregulation in MM pathogenesis.
|
17418411 |
2007 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Coordination of upregulated XBP-1 and downregulated c-myc during myeloma cell differentiation induced by 2-methoxyestradiol.
|
17257674 |
2007 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
The similarities of this model with the human disease, coupled with documented frequent XBP-1s overexpression in human MM, serve to implicate XBP-1s dysregulation in MM pathogenesis.
|
17418411 |
2007 |
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Analysis of XBP-1, a transcriptional inducer of chaperones, in freshly isolated MMCs from 22 myeloma cases revealed 10 cases with active XBP-1, who also showed significantly poorer survival (p < 0.05), suggesting that chaperone expression protects MMCs from apoptosis, thereby allowing tumor cell expansion.
|
16396777 |
2006 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
|
16002735 |
2005 |
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
XBP-1 transcripts are found at high levels in plasma cells from rheumatoid synovium and myeloma cell lines.
|
12846805 |
2003 |
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results indicate that MBP-1 and XBP-1 are IL-6 genes in myeloma cells; as such, they may play a role in IL-6-mediated growth control in multiple myeloma.
|
10375612 |
1999 |